Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration
Cerliponase alfa is recombinant human tripeptidyl peptidase 1 (TPP1) delivered by i.c.v. infusion for CLN2, a pediatric neurodegenerative disease caused by deficiency in lysosomal enzyme TPP1. We report the pharmacokinetics (PK) and pharmacodynamics of cerliponase alfa, the first i.c.v. enzyme repla...
Saved in:
Main Authors: | Aryun Kim (Author), Anita Grover (Author), Kevin Hammon (Author), Greg deHart (Author), Peter Slasor (Author), Anu Cherukuri (Author), Temitayo Ajayi (Author), David Jacoby (Author), Angela Schulz (Author), Nicola Specchio (Author), Emily deLos Reyes (Author), Paul Gissen (Author), Joshua W. Henshaw (Author) |
---|---|
Format: | Book |
Published: |
Wiley,
2021-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Dose selection for intracerebroventricular cerliponase alfa in children with CLN2 disease, translation from animal to human in a rare genetic disease
by: Kevin Hammon, et al.
Published: (2021) -
Adverse Reactions to the Orphan Drug Cerliponase Alfa in the Treatment of Neurolipofuscinosis Type 2 (CLN2)
by: Ilaria Ammendolia, et al.
Published: (2024) -
Efficacy of dual intracerebroventricular and intravitreal CLN5 gene therapy in sheep prompts the first clinical trial to treat CLN5 Batten disease
by: Samantha J. Murray, et al.
Published: (2023) -
Changing Times for CLN2 Disease: The Era of Enzyme Replacement Therapy
by: Specchio N, et al.
Published: (2020) -
Exacerbated neuronal ceroid lipofuscinosis phenotype in Cln1/5 double-knockout mice
by: Tea Blom, et al.
Published: (2013)